13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for isolating novel peptides from immunoregulatory proteins produced by pathogens that impact the immune system. 13therapeutics is moving its lead peptide, P13, forward for the prevention/treatment of noise-induced hearing loss. 13therapeutics, Inc. is an OHSU spin-off company.

AbSci is a global leader in protein production technologies. The company’s SoluPro™ expression platform achieves revolutionary yields of soluble and active protein products. AbSci’s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry.

Aronora is engaged in the commercial development of proprietary therapeutics. Rational design of its innovative therapeutic agents is expected to result in products that may be able to reduce the growth of life-threatening blood clots without the detrimental bleeding side effects characterizing antithrombotic drugs. Its products are intended for difficult-to-treat, severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases.

BV Biomed Ltd. logo image

BVBiomed is a research driven company dedicated to the discovery of novel therapeutic compounds for use in treating inflammatory autoimmune and neuro-degenerative diseases. Our primary candidate has been shown to successfully reverse the symptoms of EAE, an animal model of MS and enhance remyeliination. These neuro-protective and neuro-regenerative effects have applications in many neuro-degenerative diseases including traumatic brain injury, concussion, dementias and others. BVBiomed is currently running a clinical trial to test its efficacy in both; treating acute attacks in multiple sclerosis, its neuro-regenerative effects in these patients.

Costanoan Logo image

Costanoan Biotechnologies is bringing personalized therapeutics to patients with cancer. A development stage biotechnology company recently relocated to Portland, Costanoan is commercializing a unique bionanoparticle platform which produces custom, fully functionalized biocompaticle plastic nanoparticles in bacteria. The technology has been used as a vaccine against infectious diseases and is now being targeted at cancer, where its ‘tunability’ can modify the immune system for a patient’s specific tumor type.

Oregon‐based Floragenex is a privately owned biotechnology company providing innovative solutions for genomic analysis in the life sciences. Since 2007, Floragenex has delivered impact results in hundreds of genomics studies focused on answering fundamental questions in genetics, ecology, evolutionary biology and biomedical research. With multiple offices located on the West Coast, Floragenex technologies permit investigation of genomes at unprecedented levels for academic, governmental and commercial researchers worldwide.

GammaTherapeutics logo image

GammaTherapeutics is a biotechnology venture that develops novel medical devices for cardiovascular disease risk assessment, surgical therapy, and combat casualty care, based upon the use of human proteins responsible for the clotting mechanism in blood.

Jupiter Devices logo image

Jupiter Devices is creating a noninvasive Continuous Glucose Monitor technology (CGM) utilizing Radio Frequency (RF) analysis of the physical structure of chemical bonds to accurately measure glucose without blood extraction or hypodermic sampling of interstitial fluid. It will be small enough to fit into a watch and is intended to replace the invasive hypodermic CGM systems as well as blood glucose monitors and disposable test strips.

Madorra logo image

Madorra is developing the first non-hormonal, non-invasive medical device to treat vaginal dryness and atrophy. Madorra’s simple, easy-to-use device will empower the millions of breast cancer survivors and post-menopausal women suffering from vaginal dryness to improve their sexual health and return to wellness.

Neuralexo logo image

Neuralexo is a biotechnology company focused on the discovery and development of treatments for the protection of tissues at risk of ischemic injury (i.e. brain, heart, kidney). Indications include injury associated with cardiac surgery, transplantation, traumatic brain injury and stroke.

Oregon Heart logo image

OregonHeart is an early-stage medical device company that is developing a total artificial heart (TAH) for treatment of patients with end-stage heart failure. The company projects clinical trials to commence as early as 2020. The Knight Cardiovascular Institute at OHSU utilized a portion of a generous donation to OHSU from the Knight family to invest in developing this TAH. Our device is based on an ingenious design by OHSU Faculty member and Alumnus Dr. Richard Wampler. It combines the reliability and durability of a rotary pump with a unique shuttling action that produces pulsatile flow similar to the native cardiovascular system. The small size and widely adjustable operating parameters will allow our device to be suitable for almost all patients over 10 years of age.

Senju Pharmaceutical develops health care products for the ears, eyes, nose, skin and throat. For nearly three decades, Senju has developed ophthalmological products, recently diversifying into other areas that ensure the healthy functioning of our senses. Senju collaborates with international research initiatives, academic institutions and researchers, and industry specialists to unlock medical secrets that lead to pharmaceutical breakthroughs.

Sonivate Medical Logo image

Sonivate Medical (SMI) develops and markets innovative ultrasound technology. The company’s technology opens new markets for ultrasound by extending its use into new classes of procedures and new clinical settings. The SonicEye™, SMI’s first product, is a fingertip-mounted ultrasound probe that combines ultrasound imaging with simultaneous tactile feedback, while leaving both hands free to do work. 2012 BVC, 2013 WAC launch company winners.

Stone Table logo

StoneStable, Inc. has developed nano-technology to protect vaccines from spoilage and allows transportation and distribution at ambient temperature, eliminating the “cold-chain”. Every year 1.5 million children die from vaccine preventable diseases, many because they do not have access to vaccines. Moreover, up to 50% of vaccines, a $25 billion industry, are wasted due to problems with refrigerated transportation and storage. StoneStable, Inc. solves these problems. In addition StoneStable Inc’s technology enhances vaccine function allowing lower dosage.

Sympanoi-686x490

Sympano is a medical diagnostic point-of-care device company that uses nanotechnology to measure patient biomarkers faster, less expensively and much more sensitively than current standards. The technology has multiple applications in human health and industry.

TomeGavax-686x490

TomegaVax Inc. is an immunotherapy company that applies a game-changing vaccine technology platform to areas of unmet medical need. The company is focused on the preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV).